Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria

Molecular Genetics and Metabolism

Volumn 97, Issue 2, 2009, Pages 128-135

  Motika, Meike S ^a   Zhang, Jun ^a   Zheng, Xueying ^a   Riedler, Kiersten ^a   Cashman, John R ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

Author keywords

Flavin containing monooxygenase; FMO3; K415 frame shift; Novel mutations; Novel variants; TMAu; Trimethylaminuria; V187A

Indexed keywords

AMINO ACID; DIMETHYLANILINE MONOOXYGENASE; DIMETHYLANILINE MONOOXYGENASE 3; TRIMETHYLAMINE; TRIMETHYLAMINE OXIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; METABOLIC DISORDER; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TRIMETHYLAMINURIA;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CLONING, MOLECULAR; ENZYME STABILITY; FEMALE; GENOTYPE; HUMANS; METHYLAMINES; MOLECULAR SEQUENCE DATA; MUTATION; OXYGENASES; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 67349179951     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.02.006     Document Type: Article

References (42)

1. Cashman J.R., and Zhang J. Human flavin-containing monooxygenases. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 65-100
2. Hines R.N., Hopp K.A., Franco J., Saeian K., and Begun F.P. Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Mol. Pharmacol. 62 (2002) 320-325
3. Hernandez D., Janmohamed A., Chandan P., Phillips I.R., and Shephard E.A. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 14 (2004) 117-130
4. Motika M.S., Zhang J., and Cashman J.R. Flavin-containing monooxygenase 3 and human disease. Exp. Opin. Drug Metab. Toxicol. 3 (2007) 831-845
5. Cashman J.R., and Zhang J. Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. Drug Metab. Dispos. 30 (2002) 1043-1052
6. Cashman J.R., Camp K., Fakharzadeh S.S., Fennessey P.V., Hines R.N., Mamer O.A., Mitchell S.C., Nguyen G.P., Schlenk D., Smith R.L., Tjoa S.S., Williams D.E., and Yannicelli S. Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria. Curr. Drug Metab. 4 (2003) 151-170
7. Mitchell S.C. Trimethylaminuria: susceptibility of heterozygotes. Lancet 354 (1999) 2164-2165
8. Mitchell S.C., and Smith R.L. Trimethylaminuria: the fish malodor syndrome. Drug Metab. Dispos. 29 (2001) 517-521
9. Zhang A.Q., Mitchell S.C., and Smith R.L. Exacerbation of symptoms of fish-odour syndrome during menstruation. Lancet 348 (1996) 1740-1741
10. Yamazaki H., Fujieda M., Togashi M., Saito T., Preti G., Cashman J.R., and Kamataki T. Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients. Life Sci. 74 (2004) 2739-2747
11. Shimizu M., Yano H., Nagashima S., Murayama N., Zhang J., Cashman J.R., and Yamazaki H. Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities. Drug Metab. Dispos. 35 (2007) 328-330
12. Shimizu M., Cashman J.R., and Yamazaki H. Transient trimethylaminuria related to menstruation. BMC Med. Genet. 8 (2007) 2
13. Akerman B.R., Lemass H., Chow L.M., Lambert D.M., Greenberg C., Bibeau C., Mamer O.A., and Treacy E.P. Trimethylaminuria is caused by mutations of the FMO3 gene in a North American cohort. Mol. Genet. Metab. 68 (1999) 24-31
14. Zschocke J., Kohlmueller D., Quak E., Meissner T., Hoffmann G.F., and Mayatepek E. Mild trimethylaminuria caused by common variants in FMO3 gene. Lancet 354 (1999) 834-835
15. Chalmers R.A., Bain M.D., Michelakakis H., Zschocke J., and Iles R.A. Diagnosis and management of trimethylaminuria (FMO3 deficiency) in children. J. Inherit. Metab. Dis. 29 (2006) 162-172
16. Lomri N., Yang Z., and Cashman J.R. Expression in Escherichia coli of the flavin-containing monooxygenase D (form II) from adult human liver: determination of a distinct tertiary amine substrate specificity. Chem. Res. Toxicol. 6 (1993) 425-429
17. Nagata T., Williams D.E., and Ziegler D.M. Substrate specificities of rabbit lung and porcine liver flavin-containing monooxygenases: differences due to substrate size. Chem. Res. Toxicol. 3 (1990) 372-376
18. Zhang J., Cerny M.A., Lawson M., Mosadeghi R., and Cashman J.R. Functional activity of the mouse flavin-containing monooxygenase forms 1, 3, and 5. J. Biochem. Mol. Toxicol. 21 (2007) 206-215
19. Zhang J., Tran Q., Lattard V., and Cashman J.R. Deleterious mutations in the flavin-containing monooxygenase 3 (FMO3) gene causing trimethylaminuria. Pharmacogenetics 13 (2003) 495-500
20. Cashman J.R., Zhang J., Leushner J., and Braun A. Population distribution of human flavin-containing monooxygenase form 3: gene polymorphisms. Drug Metab. Dispos. 29 (2001) 1629-1637
21. Brunelle A., Bi Y.A., Lin J., Russell B., Luy L., Berkman C., and Cashman J. Characterization of two human flavin-containing monooxygenase (form 3) enzymes expressed in Escherichia coli as maltose binding protein fusions. Drug Metab. Dispos. 25 (1997) 1001-1007
22. Lattard V., Zhang J., Tran Q., Furnes B., Schlenk D., and Cashman J.R. Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies. Drug Metab. Dispos. 31 (2003) 854-860
23. Hamman M.A., Haehner-Daniels B.D., Wrighton S.A., Rettie A.E., and Hall S.D. Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. Biochem. Pharmacol. 60 (2000) 7-17
24. Dolan C., Shields D.C., Stanton A., O'Brien E., Lambert D.M., O'Brien J.K., and Treacy E.P. Polymorphisms of the Flavin containing monooxygenase 3 (FMO3) gene do not predispose to essential hypertension in Caucasians. BMC Med. Genet. 6 (2005) 41
25. Treacy E.P., Akerman B.R., Chow L.M., Youil R., Bibeau C., Lin J., Bruce A.G., Knight M., Danks D.M., Cashman J.R., and Forrest S.M. Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum. Mol. Genet. 7 (1998) 839-845
26. Cashman J.R. Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism. Pharmacogenomics 3 (2002) 325-339
27. Dolphin C.T., Janmohamed A., Smith R.L., Shephard E.A., and Phillips I.R. Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat. Genet. 17 (1997) 491-494
28. Yeung C.K., Adman E.T., and Rettie A.E. Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria. Arch. Biochem. Biophys. 464 (2007) 251-259
29. Borbas T., Zhang J., Cerny M.A., Liko I., and Cashman J.R. Investigation of structure and function of a catalytically efficient variant of the human flavin-containing monooxygenase form 3. Drug Metab. Dispos. 34 (2006) 1995-2002
30. Eswaramoorthy S., Bonanno J.B., Burley S.K., and Swaminathan S. Mechanism of action of a flavin-containing monooxygenase. Proc. Natl. Acad. Sci. USA 103 (2006) 9832-9837
31. Alfieri A., Malito E., Orru R., Fraaije M.W., and Mattevi A. Revealing the moonlighting role of NADP in the structure of a flavin-containing monooxygenase. Proc. Natl. Acad. Sci. USA 105 (2008) 6572-6577
32. Malito E., Alfieri A., Fraaije M.W., and Mattevi A. Crystal structure of a Baeyer-Villiger monooxygenase. Proc. Natl. Acad. Sci. USA 101 (2004) 13157-13162
33. Beaty N.B., and Ballou D.P. The oxidative half-reaction of liver microsomal FAD-containing monooxygenase. J. Biol. Chem. 256 (1981) 4619-4625
34. Beaty N.B., and Ballou D.P. The reductive half-reaction of liver microsomal FAD-containing monooxygenase. J. Biol. Chem. 256 (1981) 4611-4618
35. Jones K.C., and Ballou D.P. Reactions of the 4a-hydroperoxide of liver microsomal flavin-containing monooxygenase with nucleophilic and electrophilic substrates. J. Biol. Chem. 261 (1986) 2553-2559
36. Poulsen L.L., and Ziegler D.M. The liver microsomal FAD-containing monooxygenase. Spectral characterization and kinetic studies. J. Biol. Chem. 254 (1979) 6449-6455
37. Ziegler D.M. Flavin-containing monooxygenases: catalytic mechanism and substrate specificities. Drug Metab. Rev. 19 (1988) 1-32
38. Yamazaki H., Fujita H., Gunji T., Zhang J., Kamataki T., Cashman J.R., and Shimizu M. Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. Mol. Genet. Metab. 90 (2007) 58-63
39. Fujieda M., Yamazaki H., Togashi M., Saito T., and Kamataki T. Two novel single nucleotide polymorphisms (SNPs) of the FMO3 gene in Japanese. Drug Metab. Pharmacokinet. 18 (2003) 333-335
40. Ziegler D.M., and Mitchell C.H. Microsomal oxidase. IV. Properties of a mixed-function amine oxidase isolated from pig liver microsomes. Arch. Biochem. Biophys. 150 (1972) 116-125
41. Cashman J.R., Akerman B.R., Forrest S.M., and Treacy E.P. Population-specific polymorphisms of the human FMO3 gene: significance for detoxication. Drug Metab. Dispos. 28 (2000) 169-173
42. Lambert D.M., Mamer O.A., Akerman B.R., Choiniere L., Gaudet D., Hamet P., and Treacy E.P. In vivo variability of TMA oxidation is partially mediated by polymorphisms of the FMO3 gene. Mol. Genet. Metab. 73 (2001) 224-229